| 臺大學術典藏 |
2018-09-10T04:09:31Z |
Real-valued error control coding by using DCT
|
Wu, Ja-Ling; Shiu, Jiun; Wu, Ja-Ling |
| 朝陽科技大學 |
2009-01 |
Real-valued Feature Indexing for Music Databases
|
羅有隆; Yu-lung Lo;Ling-yi Tsai |
| 國家衛生研究院 |
2023-12-28 |
Real-world adherence to anaphylaxis guidelines among different age groups in emergency departments: A Taiwan tertiary hospital experience from 2001 to 2020
|
Ho, CH;Lee, HJ;Yeh, YH;Yu, CY;Gau, CC;Lim, JW;Huang, HY;Tsai, HJ;Yao, TC |
| 國立成功大學 |
2022 |
Real-World Analyses of the Safety Outcome among a General Population Treated with Statins: An Asian Population-Based Study
|
Lin;Jia-Ling;Chen;Po-Sheng;Lin;-Wen, Hui;Tsai;Liang-Miin;Lin;Sheng-Hsiang;Li;Yi-Heng |
| 國立成功大學 |
2023 |
Real-World Analyses of the Treatment Conditions in Patients Initiating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor in Taiwan
|
Lin, P.-L.;Wu, Y.-W.;Lin, C.-F.;Yeh, H.-I.;Chang, W.-T.;Charng, M.-J.;Huang, P.-H.;Lin, C.-C.;Lin, T.-H.;Lin, W.-W.;Hsieh, I.-C.;Kuo, F.-Y.;Chen, Chen C.-P.;Li, Y.-H. |
| 臺大學術典藏 |
2021-05-24T07:20:23Z |
Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study
|
CHEN-HUA LIU; Yu M.-L.; Peng C.-Y.; Hsieh T.-Y.; Huang Y.-H.; Su W.-W.; Cheng P.-N.; Lin C.-L.; Lo C.-C.; Chen C.-Y.; Chen J.-J.; Ma Q.; Brooks-Rooney C.; Kao J.-H. |
| 臺大學術典藏 |
2021-09-04T05:16:51Z |
Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study
|
Liu C.-H.; Yu M.-L.; Peng C.-Y.; Hsieh T.-Y.; Huang Y.-H.; Su W.-W.; Cheng P.-N.; Lin C.-L.; Lo C.-C.; Chen C.-Y.; Chen J.-J.; Ma Q.; Brooks-Rooney C.; JIA-HORNG KAO |
| 國立成功大學 |
2019 |
Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study
|
Liu, C.-H.;Yu, M.-L.;Peng, C.-Y.;Hsieh, T.-Y.;Huang, Y.-H.;Su, W.-W.;Cheng, P.-N.;Lin, C.-L.;Lo, C.-C.;Chen, Chen C.-Y.;Chen, J.-J.;Ma, Q.;Brooks-Rooney, C.;Kao, J.-H. |
| 國立成功大學 |
2023 |
Real-world bleeding outcomes and product utilization in people with severe-type hemophilia A before and after switching to extended half-life rFVIIIFc prophylaxis therapy
|
Chang, Chang C.-Y.;Lai, S.-W.;Cheng, M.-M.;Ku, J.-T.;Hu, S.-H.;Liu, Y.-L.;Tsai, J.-R.;Tsai, C.-H.;Cheng, Cheng C.-N.;Chen, Y.-C. |
| 嘉南藥理大學 |
2022 |
Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma
|
Kuo, Hsin-Yu; Han, Meng-Zhi; Liao, Chih-Hsiang; Lin, Yih-Jyh; Wang, Chung-Teng; Chen, Shang-Hung; Chang, Ting-Tsung; Chen, Po-Jun; Lin, Sheng-Hsiang; Chen, Chiung-Yu; Chuang, Chiao-Hsiung; Wu, I-Chin; Wu, Juei-Seng; Hong, Tzu-Chun; Hsieh, Ming-Tsung; Lee, Yang-Cheng; Wu, Hung-Tsung; Tsai, Hong-Ming |
| 國家衛生研究院 |
2022-10-23 |
Real-world comparative effectiveness of nivolumab versus pembrolizumab in patients with unresectable hepatocellular carcinoma
|
Kuo, HY;Han, MZ;Liao, CH;Lin, YJ;Wang, CT;Chen, SH;Chang, TT;Chen, PJ;Lin, SH;Chen, CY;Chuang, CH;Wu, IC;Wu, JS;Hong, TC;Hsieh, MT;Lee, YC;Wu, HT;Tsai, HM |
| 國立成功大學 |
2022-11 |
Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma
|
Kuo;Hsin-Yu;Han;Meng-Zhi;Liao;Chih-Hsiang;Lin;Yih-Jyh;Wang;Chung-Teng;Chen;Shang-Hung;Chang;Ting-Tsung;Chen;Po-Jun;Lin;Sheng-Hsiang;Chen;Chiung-Yu;Chuang;Chiao-Hsiung;Wu;I-Chin;Wu;Juei-Seng;Hong;Tzu-Chun;Hsieh;Ming-Tsung;Lee;Yang-Cheng;Wu;Hung-Tsung;Tsai;Hong-Ming |
| 國立成功大學 |
2022-12 |
Real-World Comparative Evaluation of Add-On Glucagon-like Peptide 1 Receptor Agonist in Type 2 Diabetes Treated with or without Insulin
|
Chou;Hsuan-Wen;Cheng;Kai-Pi;Lin;An-Chi;Hung;Hao-Chang;Lin;Ching-Han;Wang;Chih-Chen;Wu;Hung-Tsung;Ou;Horng-Yih |
| 臺大學術典藏 |
2021-07-15T05:32:09Z |
Real-world cost-effectiveness analysis of the fracture liaison services model of care for hip fracture in Taiwan
|
Chien, Li Nien; Li, Yi Fan; RONG-SEN YANG; Yang, Tsung Han; Chen, Yi Han; Huang, Wei Jia; Tsai, Hsin Yi; Li, Chun Yi; DING-CHENG CHAN |
| 臺大學術典藏 |
2022-04-07T02:21:28Z |
Real-world cost-effectiveness analysis of the fracture liaison services model of care for hip fracture in Taiwan
|
Chien, Li-Nien; Li, Yi-Fan; Yang, Rong-Sen; Yang, Tsung-Han; Chen, Yi-Han; Huang, Wei-Jia; Tsai, Hsin-Yi; Li, Chun-Yi; DING-CHENG CHAN |
| 國立成功大學 |
2021 |
Real-world cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis in Taiwan
|
Johnson, B.;Lai, E.C.-C.;Ou, H.-T.;Li, H.;Stollenwerk, B. |
| 美和科技大學 |
2019-09-30 |
Real-world Cost-effectiveness of Drug-eluting Stents vs. Bare-metal Stents for Coronary Heart Disease – A Five-year Follow-up Study
|
Tran1, Hoai Phuong;Wang, Mei-Hua |
| 美和科技大學 |
2019-09-25 |
Real-world Cost-effectiveness of Drug-eluting Stents vs. Bare-metal Stents for Coronary Heart Disease – A Five-year Follow-up Study
|
Cheng, Hao-Min;Chioue, Ling-Jan;Chen, Tzu-Ching;Sung, Shih-Hsien;Chen, Chen-Huan;Lang, Hui-Chu |
| 臺大學術典藏 |
2019-07-16T05:34:47Z |
Real-world cost-effectiveness of laparoscopy versus open colectomy for colon cancer: a nationwide population-based study
|
Liao C.-H.;Tan E.C.-H.;Chen C.-C.;Ming-Chin Yang; Liao C.-H.; Tan E.C.-H.; Chen C.-C.; MING-CHIN YANG |
| 臺大學術典藏 |
2020-05-20T05:27:09Z |
Real-World Crizotinib Use for Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer under First-Year National Health Insurance Coverage in Taiwan
|
JIN-YUAN SHIH;CHUNG-YU CHEN;YEN-TING LIN; YEN-TING LIN; CHUNG-YU CHEN; JIN-YUAN SHIH |
| 臺大學術典藏 |
2018-09-10T18:04:10Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Yao, Z.-H. and Liao, W.-Y. and Ho, C.-C. and Chen, K.-Y. and Shih, J.-Y. and Chen, J.-S. and Lin, Z.-Z. and Lin, C.-C. and Yang, J.C.H. and Yu, C.-J.; Chong-Jen Yu; WEI-YU LIAO; JIN-YUAN SHIH; JIN-SHING CHEN |
| 臺大學術典藏 |
2020-03-30T08:50:53Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Shih J.-Y.; JIN-SHING CHEN; Lin Z.-Z.; Lin C.-C.; Yang J.C.H.; Yu C.-J.; Yao Z.-H.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Shih J.-Y.;Jin-Shing Chen;Lin Z.-Z.;Lin C.-C.;Yang J.C.H.;Yu C.-J.; Yao Z.-H.; Liao W.-Y.; Ho C.-C.; Chen K.-Y. |
| 臺大學術典藏 |
2020-05-25T07:35:15Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Ho C.-C; Chen K.-Y; Shih J.-Y; Chen J.-S; Lin Z.-Z; Chia-Chi Lin; Yang J.C.H; Yu C.-J.; Yao Z.-H; Liao W.-Y |
| 臺大學術典藏 |
2020-07-21T06:09:09Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Yu C.-J.; Yang J.C.H.; Yao Z.-H.;Wei-Yu Liao;Ho C.-C.;Chen K.-Y.;Shih J.-Y.;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.H.;Yu C.-J.; Yao Z.-H.; WEI-YU LIAO; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C. |
| 臺大學術典藏 |
2020-07-21T06:46:22Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Yang J.C.H.; Yu C.-J.; Lin C.-C.; Yao Z.-H.; Lin Z.-Z.; Chen J.-S.; Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Shih J.-Y. |
| 臺大學術典藏 |
2020-08-12T02:50:42Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Lin C.-C.; Yang J.C.H.; Yu C.-J.; Lin Z.-Z.; Chen J.-S.; Yao Z.-H.; Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Shih J.-Y.; Yao Z.-H.;Liao W.-Y.;Chao-Chi Ho;Chen K.-Y.;Shih J.-Y.;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.H.;Yu C.-J. |
| 臺大學術典藏 |
2020-08-12T06:34:29Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Yang J.C.H.; CHONG-JEN YU; Chen K.-Y.; Shih J.-Y.; Ho C.-C.; Liao W.-Y.; Yao Z.-H.; Yao Z.-H.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Shih J.-Y.;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.H.;Chong-Jen Yu |
| 臺大學術典藏 |
2017 |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Yu C.-J.; Yang J.C.H.; Lin C.-C.; Lin Z.-Z.; Chen J.-S.; JIN-YUAN SHIH; Chen K.-Y.; Ho C.-C.; Liao W.-Y.; Yao Z.-H.; Yao Z.-H.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Jin-Yuan Shih;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.H.;Yu C.-J. |
| 臺大學術典藏 |
2020-05-26T09:26:36Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Yu C.-J.;Chih-Hsin Yang;Lin C.-C;Lin Z.-Z;Chen J.-S;Shih J.-Y;Chen K.-Y;Ho C.-C;Liao W.-Y;Yao Z.-H; Yao Z.-H; Liao W.-Y; Ho C.-C; Chen K.-Y; Shih J.-Y; Chen J.-S; Lin Z.-Z; Lin C.-C; CHIH-HSIN YANG; Yu C.-J. |
| 臺大學術典藏 |
2021-04-29T05:08:55Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Yao Z.-H.; Liao W.-Y.; Ho C.-C.; KUAN-YU CHEN; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Yang J.C.H.; Yu C.-J. |
| 臺大學術典藏 |
2021-08-11T03:46:38Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Yao Z.-H.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; ZHONG-ZHE LIN; Lin C.-C.; Yang J.C.H.; Yu C.-J. |
| 臺大學術典藏 |
2021-04-29T02:38:33Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Anonymous |
| 臺大學術典藏 |
2021-09-09T05:25:29Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
ZONG-HAN YAO; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Yang J.C.H.; Yu C.-J. |
| 臺大學術典藏 |
2022-06-10T06:11:00Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Yao Z.-H.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; ZHONG-ZHE LIN; Lin C.-C.; Yang J.C.H.; Yu C.-J. |
| 臺大學術典藏 |
2022-06-27T07:00:07Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Yao Z.-H.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Yang J.C.H.; CHONG-JEN YU |
| 國家衛生研究院 |
2023-02-05 |
Real-world data validation of NAPOLI-1 nomogram for the prediction of overall survival in metastatic pancreatic cancer
|
Su, YY;Chiang, NJ;Yang, YH;Yen, CJ;Bai, LY;Chiu, CF;Chuang, SC;Yang, SH;Chou, WC;Chen, JS;Chiu, TJ;Chen, YY;Chan, DC;Peng, CM;Chiu, SC;Li, CP;Shan, YS;Chen, LT |
| 國立成功大學 |
2023-02 |
Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer
|
Su;Yung-Yeh;Chiang;Nai-Jung;Yang;Yi-Hsin;Yen;Chia-Jui;Bai;Li-Yuan;Chiu;Chang-Fang;Chuang;Shih-Chang;Yang;Shih-Hung;Chou;Wen-Chi;Chen;Jen-Shi;Chiu;Tai-Jan;Chen;Yen-Yang;Chan;De-Chuan;Peng;Cheng-Ming;Chiu;Sz-Chi;Li;Chung-Pin;Shan;Yan-Shen;Chen;Li-Tzong |
| 臺大學術典藏 |
2019 |
Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C
|
Hsu S.-J.; Chiu M.-C.; Fang Y.-J.; Yang T.-H.; Yu J.-J.; CHIEH-CHANG CHEN; Kuo C.-C.; Lee J.-Y.; Chen C.-H.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-02-22T05:34:12Z |
Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C
|
Hsu S.-J.; Chiu M.-C.; Fang Y.-J.; Yang T.-H.; Yu J.-J.; Chen C.-C.; Kuo C.-C.; Lee J.-Y.; CHIEN-HUNG CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-02-14T06:28:47Z |
Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C
|
Hsu S.-J.; Chiu M.-C.; YU-JEN FANG; Yang T.-H.; Yu J.-J.; Chen C.-C.; Kuo C.-C.; Lee J.-Y.; Chen C.-H.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-02-18T08:25:58Z |
Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C
|
Hsu S.-J.; Chiu M.-C.; Fang Y.-J.; Yang T.-H.; Yu J.-J.; CHIEH-CHANG CHEN; Kuo C.-C.; Lee J.-Y.; Chen C.-H.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-02-23T02:12:23Z |
Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C
|
Hsu S.-J.; Chiu M.-C.; Fang Y.-J.; Yang T.-H.; Yu J.-J.; Chen C.-C.; Kuo C.-C.; Lee J.-Y.; CHIEN-HUNG CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-09-04T05:16:49Z |
Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C
|
Hsu S.-J.; Chiu M.-C.; Fang Y.-J.; Yang T.-H.; Yu J.-J.; Chen C.-C.; Kuo C.-C.; Lee J.-Y.; Chen C.-H.; Chen D.-S.; JIA-HORNG KAO |
| 國立成功大學 |
2020-03-01 |
Real-world effectiveness and safety of ledipasvir/sofosbuvir for genotype 6 chronic hepatitis C patients in Taiwan
|
鄭斌男; 陳志州;李佩倫;邱宏志;董宏達;邱彥程 |
| 國立成功大學 |
2020-03 |
Real-world effectiveness and safety of ledipasvir/sofosbuvir for genotype 6 chronic hepatitis C patients in Taiwan
|
Chen;Jyh-Jou;Lee;Pei-Lun;Chiu;Hung-Chih;Tung;Hung-Da;Chiu;Yen-Cheng;Cheng;Pin-Nan |
| 臺大學術典藏 |
2021-05-24T07:20:28Z |
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
|
CHEN-HUA LIU; Liu C.-J.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:33:40Z |
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
|
Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; PEI-JER CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-12T02:44:33Z |
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
|
Liu C.-H; | Liu C.-J; | Su T.-H; | HUNG-CHIH YANG; | Hong C.-M; | Tseng T.-C; | Chen P.-J; | Chen D.-S; | Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:21Z |
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
|
Liu C.-H.; CHUN-JEN LIU; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:23Z |
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
|
Liu C.-H.; Liu C.-J.; TUNG-HUNG SU; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
